Table A2: Cocaine
| Prevalence estimates | Entrants into treatment during the year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| General population | School population | Cocaine clients as % of treatment entrants | % cocaine clients injecting (main route of administration) | |||||||
| Year of survey | Lifetime, adults (15–64) | Last 12 months, young adults (15–34) | Lifetime, students (15–16) | All entrants | First-time entrants | Previously treated entrants | All clients | First-time entrants | Previously treated entrants | |
| Country | % | % | % | % (count) | % (count) | % (count) | % (count) | % (count) | % (count) | |
| Belgium 1 | 2013 | - | 0.9 | 3 | 18.9 (2 207) | 18.9 (756) | 18.9 (1 401) | 6.5 (125) | 1.1 (7) | 9.4 (115) |
| Bulgaria | 2012 | 0.9 | 0.3 | 5 | 1.6 (29) | 6.5 (21) | 0.8 (8) | 7.1 (2) | 0 (0) | 25 (2) |
| Czech Republic | 2015 | 1.8 | 0.3 | 1 | 0.3 (27) | 0.3 (12) | 0.3 (15) | 0 (0) | 0 (0) | 0 (0) |
| Denmark | 2013 | 5.2 | 2.4 | 2 | 5.5 (260) | 5.9 (134) | 5.4 (124) | 3.9 (8) | – | 8.6 (8) |
| Germany 3 | 2015 | 3.8 | 1.2 | 3 | 6 (5 209) | 5.6 (1 494) | 6.1 (3 715) | 17.1 (2 843) | 8.8 (353) | 19.7 (2 490) |
| Estonia | 2008 | – | 1.3 | 1 | 0.7 (2) | – | 1.2 (2) | 50 (1) | – | 50 (1) |
| Ireland | 2015 | 7.8 | 2.9 | 3 | 10.5 (996) | 13.7 (513) | 8.4 (457) | 0.8 (8) | 0.2 (1) | 1.6 (7) |
| Greece | – | – | – | 1 | 6.6 (269) | 8.9 (141) | 5.2 (128) | 11.6 (31) | 4.3 (6) | 19.5 (25) |
| Spain | 2015 | 9.1 | 3.0 | 2 | 36.5 (17 864) | 34.8 (8 234) | 37 (6 954) | 1.3 (224) | 0.7 (56) | 2.1 (141) |
| France | 2014 | 5.4 | 2.4 | 4 | 6.1 (3 013) | 6.1 (963) | 8.1 (1 369) | 10.2 (269) | 3.6 (32) | 16.5 (198) |
| Croatia | 2015 | 2.7 | 1.6 | 2 | 1.4 (104) | 2.8 (24) | 1.2 (80) | 2 (2) | – | 2.5 (2) |
| Italy | 2014 | 7.6 | 1.8 | 3 | 25.3 (11 935) | 30.4 (6 296) | 21.3 (5 639) | 4.2 (479) | 2.6 (159) | 5.9 (320) |
| Cyprus | 2016 | 1.4 | 0.4 | 3 | 10 (80) | 8.3 (36) | 11.8 (38) | 5.1 (4) | 0 (0) | 7.9 (3) |
| Latvia | 2015 | 1.5 | 1.2 | 2 | 1.2 (9) | 1.8 (7) | 0.6 (2) | 0 (0) | 0 (0) | 0 (0) |
| Lithuania | 2012 | 0.9 | 0.3 | 2 | 0.6 (15) | 1.8 (7) | 0.3 (7) | 13.3 (2) | 14.3 (1) | 14.3 (1) |
| Luxembourg | – | – | – | – | 19 (55) | 16.7 (4) | 20.4 (44) | 44.4 (24) | – | 50 (22) |
| Hungary 3 | 2015 | 1.2 | 0.9 | 2 | 2.3 (99) | 2.5 (75) | 1.7 (19) | 5.2 (5) | 1.4 (1) | 15.8 (3) |
| Malta | 2013 | 0.5 | – | 3 | 15.9 (281) | 39.6 (91) | 12.3 (190) | 17.6 (45) | 8.1 (7) | 22.4 (38) |
| Netherlands | 2015 | 5.1 | 3.6 | 2 | 24.3 (2 675) | 20.8 (1 357) | 29.6 (1 318) | 0.4 (5) | 0.1 (1) | 0.6 (4) |
| Austria | 2015 | 3 0 | 4 2 | 7 | 1 (258) | 9.6 (125) | 5.7 (133) | 6.3 (15) | 0.8 (1) | 11.6 (14) |
| Poland | 2014 | 1.3 | 0.4 | 4 | 2.1 (189) | 1.9 (83) | 2.3 (101) | 2.2 (4) | 1.3 (1) | 3 (3) |
| Portugal | 2012 | 1.2 | 0.4 | 2 | 12 (331) | 15.1 (239) | 7.9 (92) | 4.4 (13) | 2.3 (5) | 9.6 (8) |
| Romania | 2013 | 0.8 | 0.2 | 3 | 0.6 (19) | 0.9 (18) | 0 (0) | 0 (0) | 0 (0) | – |
| Slovenia | 2012 | 2.1 | 1.2 | 2 | 4.1 (13) | 9.1 (8) | 2.2 (5) | 23.1 (3) | 0 (0) | 60 (3) |
| Slovakia | 2015 | 0.7 | 0.3 | 2 | 0.8 (19) | 0.7 (9) | 0.7 (9) | 5.9 (1) | – | 12.5 (1) |
| Finland | 2014 | 1.9 | 1.0 | 1 | 0 (0) | 0 (0) | 0 (0) | – | – | - |
| Sweden 4 5 | 2013 | – | 1.2 | 2 | 0.9 (318) | 1.7 (211) | 0.5 (103) | 0 (0) | 0 (0) | 0 (0) |
| United Kingdom 2 4 | 2015 | 9.7 | 4.0 | 2 | 13.9 (16 673) | 17.2 (6 830) | 12.2 (9 806) | 1.5 (168) | 0.4 (18) | 2.3 (146) |
| Turkey | 2011 | – | – | – | 1.8 (198) | 1.5 (79) | 2.2 (119) | – | – | - |
| Norway 4 | 2015 | 4.2 | 2.2 | 1 | 1.4 (83) | – | – | – | – | - |
| European Union | – | 5.2 | 1.9 | – | 13 (62 949) | 15.4 (27 688) | 11.4 (31 759) | 6.5 (4 281) | 2.4 (649) | 10 (3 556) |
| EU, Turkey and Norway | – | – | – | – | 12.6 (63 230) | 15 (27 767) | 11.2 (31 878) | 6.5 (4 281) | 2.4 (649) | 10 (3 556) |
NB
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, Latvia data may not be comparable.
- Prevalence estimates for the general population refer to Flanders only. ↩
- Prevalence estimates for the general population refer to England and Wales only. ↩
- Age range for prevalence estimates in the general population: 18–64, 18–34. ↩
- Age range for prevalence estimates in the general population: 16–64, 16–34. ↩
- First-time and previously treated entrants are available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all entrants. ↩